{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:58:56Z","timestamp":1768989536071,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jiac.2024.02.026","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T11:13:24Z","timestamp":1709118804000},"page":"853-859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Difference in the impact of coinfections and secondary infections on antibiotic use in patients hospitalized with COVID-19 between the Omicron-dominant period and the pre-Omicron period"],"prefix":"10.1016","volume":"30","author":[{"given":"Yasushi","family":"Murakami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Morosawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ogashiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-6416","authenticated-orcid":false,"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.02.026_bib1","article-title":"Bacterial and fungal superinfections are detected at higher frequency in critically ill patients affected by SARS CoV-2 infection than negative patients and are associated to a worse outcome","volume":"95","author":"De Francesco","year":"2023","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.jiac.2024.02.026_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106324","article-title":"Increased antimicrobial resistance during the COVID-19 pandemic","volume":"57","author":"Lai","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jiac.2024.02.026_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13756-022-01085-z","article-title":"Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021)","volume":"11","author":"Kariyawasam","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"issue":"3","key":"10.1016\/j.jiac.2024.02.026_bib4","first-page":"338","article-title":"Increment antimicrobial resistance during the COVID-19 pandemic: results from the invifar Network","volume":"28","author":"Lopez-Jacome","year":"2022","journal-title":"Microb Drug Resist"},{"issue":"2","key":"10.1016\/j.jiac.2024.02.026_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020518","article-title":"Correlation between antimicrobial resistance and the hospital-wide diverse use of broad-spectrum antibiotics by the antimicrobial stewardship program in Japan","volume":"15","author":"Ueda","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.jiac.2024.02.026_bib6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s15010-021-01602-z","article-title":"State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia","volume":"49","author":"Chong","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2024.02.026_bib7","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.2147\/JIR.S420721","article-title":"Differential characteristics of patients for hospitalized severe COVID-19 infected by the Omicron variants and wild type of SARS-CoV-2 in China","volume":"16","author":"Wei","year":"2023","journal-title":"J Inflamm Res"},{"issue":"1","key":"10.1016\/j.jiac.2024.02.026_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13054-023-04312-0","article-title":"COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation","volume":"27","author":"Patton","year":"2023","journal-title":"Crit Care"},{"issue":"7902","key":"10.1016\/j.jiac.2024.02.026_bib9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41586-022-04462-1","article-title":"Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant","volume":"603","author":"Suzuki","year":"2022","journal-title":"Nature"},{"issue":"7902","key":"10.1016\/j.jiac.2024.02.026_bib10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","article-title":"Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron","volume":"603","author":"Shuai","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jiac.2024.02.026_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/v14061297","article-title":"Clinical severity of SARS-CoV-2 Omicron variant compared with Delta among hospitalized COVID-19 patients in Belgium during autumn and winter season 2021-2022","volume":"14","author":"Van Goethem","year":"2022","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.jiac.2024.02.026_bib12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cmi.2023.03.017","article-title":"Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients","volume":"29","author":"Hu","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.jiac.2024.02.026_bib13","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/jmv.27697","article-title":"Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review","volume":"94","author":"Chenchula","year":"2022","journal-title":"J Med Virol"},{"issue":"6","key":"10.1016\/j.jiac.2024.02.026_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.15585\/mmwr.mm7106e2","volume":"71","author":"Modes","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jiac.2024.02.026_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140491","article-title":"Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection","volume":"131","author":"Files","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jiac.2024.02.026_bib16","unstructured":"Clinical spectrum | COVID-19 treatment guidelines (nih.gov) accessed 9 February 2024."},{"key":"10.1016\/j.jiac.2024.02.026_bib17","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1097\/CCM.0000000000004363","article-title":"Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)","volume":"48","author":"Alhazzani","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiac.2024.02.026_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jiac.2024.02.026_bib19","unstructured":"Clinical guidance for COVID-19 vaccination | CDC (accessed 5 October 2023)."},{"issue":"2","key":"10.1016\/j.jiac.2024.02.026_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/cid\/ciy075","article-title":"The standardized antimicrobial administration ratio: a new metric for measuring and comparing antibiotic use","volume":"67","author":"van Santen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.02.026_bib21","unstructured":"European committee on antimicrobial susceptibility testing: the implementation of the new definition of S, I, and R. EUCAST\u2014intermediate category (accessed 9 March 2023)."},{"key":"10.1016\/j.jiac.2024.02.026_bib22","unstructured":"https:\/\/www.japantimes.co.jp\/news\/2021\/10\/05\/national\/japan-vaccination-rate-60-percent\/accessed January 10 2024."},{"issue":"11","key":"10.1016\/j.jiac.2024.02.026_bib23","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s11604-020-01010-7","article-title":"Chest computed tomography findings of COVID-19 pneumonia: pictorial essay with literature review","volume":"38","author":"Cellina","year":"2020","journal-title":"Jpn J Radiol"},{"issue":"4","key":"10.1016\/j.jiac.2024.02.026_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284806","article-title":"Comparison of antibiotic use and antibiotic resistance between a community hospital and tertiary care hospital for evaluation of the antimicrobial stewardship program in Japan","volume":"18","author":"Morosawa","year":"2023","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jiac.2024.02.026_bib25","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1007\/s00330-020-06801-0","article-title":"Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review","volume":"30","author":"Ye","year":"2020","journal-title":"Eur Radiol"},{"issue":"5","key":"10.1016\/j.jiac.2024.02.026_bib26","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s15010-021-01615-8","article-title":"C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19","volume":"49","author":"Pink","year":"2021","journal-title":"Infection"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24000679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24000679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T16:32:47Z","timestamp":1738686767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1341321X24000679"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.02.026","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Difference in the impact of coinfections and secondary infections on antibiotic use in patients hospitalized with COVID-19 between the Omicron-dominant period and the pre-Omicron period","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}